The abstract is read at the publisher; the summary is JClub's.
Adjuvant selpercatinib significantly improves 2-year investigator-assessed event-free survival versus placebo in stage II or IIIA RET fusion-positive NSCLC, 92% vs 61%.
- Why it matters: Early-stage RET fusion-positive NSCLC lacks evidence on whether selpercatinib after curative-intent therapy can reduce recurrence, progression, or death.
- What they did: In a phase 3 double-blind trial, 151 patients with RET fusion-positive NSCLC were randomized to up to 3 years of adjuvant selpercatinib or placebo; the primary endpoint was investigator-assessed event-free survival in stage II or IIIA disease.
- The result: For 109 stage II/IIIA patients, the hazard ratio for disease recurrence, progression, or death was 0.17 (95% CI, 0.06 to 0.51; P<0.001), with consistent results from blinded independent central review and grade ≥3 alanine aminotransferase/aspartate aminotransferase in 17%/19%.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.